Janeway's

immuno biology

SEVENTH EDITION



Kenneth Murphy • Paul Travers • Mark Walport

Contents

PART I **AN INTRODUCTION TO IMMUNOBIOLOGY AND INNATE IMMUNITY**

Chapter 1	Basic Concepts in Immunology	1
Chapter 2	Innate Immunity	39

PART II **THE RECOGNITION OF ANTIGEN**

Chapter 3	Antigen Recognition by B-cell and T-cell Receptors	111
Chapter 4	The Generation of Lymphocyte Antigen Receptors	143
Chapter 5	Antigen Presentation to T Lymphocytes	181

PART III **THE DEVELOPMENT OF MATURE LYMPHOCYTE RECEPTOR REPERTOIRES**

Chapter 6	Signaling Through Immune System Receptors	219
Chapter 7	The Development and Survival of Lymphocytes	257

PART IV **THE ADAPTIVE IMMUNE RESPONSE**

Chapter 8	T Cell-Mediated Immunity	323
Chapter 9	The Humoral Immune Response	379
Chapter 10	Dynamics of Adaptive Immunity	421
Chapter 11	The Mucosal Immune System	459

PART V **THE IMMUNE SYSTEM IN HEALTH AND DISEASE**

Chapter 12	Failures of Host Defense Mechanism	497
Chapter 13	Allergy and Hypersensitivity	555
Chapter 14	Autoimmunity and Transplantation	599
Chapter 15	Manipulation of the Immune Response	655

PART VI **THE ORIGINS OF IMMUNE RESPONSES**

Chapter 16	Evolution of the Immune System	711

Appendix I Immunologists' Toolbox	735
Appendix II CD Antigens	783
Appendix III Cytokines and their Receptors	799
Appendix IV Chemokines and their Receptors	802
Appendix V Immunological Constants	804
Biographies	805
Glossary	806
Index	835

Detailed Contents

Part I AN INTRODUCTION TO IMMUNOBIOLOGY AND INNATE IMMUNITY

Chapter 1 Basic Concepts in Immunology **1**

Principles of innate and adaptive immunity. **3**

1-1 Functions of the immune response. 3
1-2 The cells of the immune system derive from precursors in the bone marrow. 5
1-3 The myeloid lineage comprises most of the cells of the innate immune system. 5
1-4 The lymphoid lineage comprises the lymphocytes of the adaptive immune system and the natural killer cells of innate immunity. 8
1-5 Lymphocytes mature in the bone marrow or the thymus and then congregate in lymphoid tissues throughout the body. 9
1-6 Most infectious agents activate the innate immune system and induce an inflammatory response. 10
1-7 Activation of specialized antigen-presenting cells is a necessary first step for induction of adaptive immunity. 12
1-8 The innate immune system provides an initial discrimination between self and nonself. 13
1-9 Lymphocytes activated by antigen give rise to clones of antigen-specific effector cells that mediate adaptive immunity. 13
1-10 Clonal selection of lymphocytes is the central principle of adaptive immunity. 14
1-11 The structure of the antibody molecule illustrates the central puzzle of adaptive immunity. 15
1-12 Each developing lymphocyte generates a unique antigen receptor by rearranging its receptor gene segments. 16
1-13 Immunoglobulins bind a wide variety of chemical structures, whereas the T-cell receptor is specialized to recognize foreign antigens as peptide fragments bound to proteins of the major histocompatibility complex. 17
1-14 The development and survival of lymphocytes is determined by signals received through their antigen receptors. 18
1-15 Lymphocytes encounter and respond to antigen in the peripheral lymphoid organs. 18
1-16 Interaction with other cells as well as with antigen is necessary for lymphocyte activation. 23
1-17 Lymphocytes activated by antigen proliferate in the peripheral lymphoid organs, generating effector cells and immunological memory. 23
Summary. 27

The effector mechanisms of adaptive immunity. **27**

1-18 Antibodies deal with extracellular forms of pathogens and their toxic products. 28
1-19 T cells are needed to control intracellular pathogens and to activate B-cell responses to most antigens. 30
1-20 CD4 and CD8 T cells recognize peptides bound to two different classes of MHC molecules. 32
1-21 Defects in the immune system result in increased susceptibility to infection. 34
1-22 Understanding adaptive immune responses is important for the control of allergies, autoimmune disease, and organ graft rejection. 34
1-23 Vaccination is the most effective means of controlling infectious diseases. 36
Summary. 37
Summary to Chapter 1. 37

Chapter 2 Innate Immunity **39**

The front line of host defense. **40**

2-1 Infectious diseases are caused by diverse living agents that replicate in their hosts. 41
2-2 Infectious agents must overcome innate host defenses to establish a focus of infection. 44
2-3 The epithelial surfaces of the body make up the first lines of defense against infection. 46
2-4 After entering tissues, many pathogens are recognized, ingested, and killed by phagocytes. 48
2-5 Pathogen recognition and tissue damage initiate an inflammatory response. 50
Summary. 52

Pattern recognition in the innate immune system. **53**

2-6 Receptors with specificity for pathogen molecules recognize patterns of repeating structural motifs. 54
2-7 The Toll-like receptors are signaling receptors that distinguish different types of pathogen and help direct an appropriate immune response. 56
2-8 The effects of bacterial lipopolysaccharide on macrophages are mediated by CD14 binding to TLR-4. 57
2-9 The NOD proteins act as intracellular sensors of bacterial infection. 58
2-10 Activation of Toll-like receptors and NOD proteins triggers the production of pro-inflammatory cytokines and chemokines, and the expression of co-stimulatory molecules. 58
Summary. 59

The complement system and innate immunity. **61**

2-11 Complement is a system of plasma proteins that is activated by the presence of pathogens. 61
2-12 Complement interacts with pathogens to mark them for destruction by phagocytes. 62
2-13 The classical pathway is initiated by activation of the C1 complex. 64
2-14 The lectin pathway is homologous to the classical pathway. 65
2-15 Complement activation is largely confined to the surface on which it is initiated. 67
2-16 Hydrolysis of C3 causes initiation of the alternative pathway of complement. 69

2-17 Membrane and plasma proteins that regulate the formation and stability of C3 convertases determine the extent of complement activation under different circumstances. 69
2-18 Surface-bound C3 convertase deposits large numbers of C3b fragments on pathogen surfaces and generates C5 convertase activity. 73
2-19 Ingestion of complement-tagged pathogens by phagocytes is mediated by receptors for the bound complement proteins. 73
2-20 Small fragments of some complement proteins can initiate a local inflammatory response. 75
2-21 The terminal complement proteins polymerize to form pores in membranes that can kill certain pathogens. 75
2-22 Complement control proteins regulate all three pathways of complement activation and protect the host from its destructive effects. 78
Summary. 81

Induced innate responses to infection. 82

2-23 Activated macrophages secrete a range of cytokines that have a variety of local and distant effects. 83
2-24 Chemokines released by phagocytes and dendritic cells recruit cells to sites of infection. 83
2-25 Cell-adhesion molecules control interactions between leukocytes and endothelial cells during an inflammatory response. 87
2-26 Neutrophils make up the first wave of cells that cross the blood vessel wall to enter inflammatory sites. 88
2-27 TNF-α is an important cytokine that triggers local containment of infection but induces shock when released systemically. 90
2-28 Cytokines released by phagocytes activate the acute-phase response. 92
2-29 Interferons induced by viral infection make several contributions to host defense. 94
2-30 NK cells are activated by interferons and macrophage-derived cytokines to serve as an early defense against certain intracellular infections. 95
2-31 NK cells possess receptors for self molecules that prevent their activation by uninfected cells. 96
2-32 NK cells bear receptors that activate their killer function in response to ligands expressed on infected cells or tumor cells. 99
2-33 The NKG2D receptor activates a different signaling pathway from that of the other activating NK receptors. 100
2-34 Several lymphocyte subpopulations behave as innate-like lymphocytes. 100
Summary. 102
Summary to Chapter 2. 103

Part II THE RECOGNITION OF ANTIGEN

Chapter 3 Antigen Recognition by B-cell and T-cell Receptors 111

The structure of a typical antibody molecule. 112

3-1 IgG antibodies consist of four polypeptide chains. 113
3-2 Immunoglobulin heavy and light chains are composed of constant and variable regions. 113
3-3 The antibody molecule can readily be cleaved into functionally distinct fragments. 114
3-4 The immunoglobulin molecule is flexible, especially at the hinge region. 115
3-5 The domains of an immunoglobulin molecule have similar structures. 116
Summary. 118

The interaction of the antibody molecule with specific antigen. 118

3-6 Localized regions of hypervariable sequence form the antigen-binding site. 118
3-7 Antibodies bind antigens via contacts with amino acids in CDRs, but the details of binding depend upon the size and shape of the antigen. 119
3-8 Antibodies bind to conformational shapes on the surfaces of antigens. 120
3-9 Antigen–antibody interactions involve a variety of forces. 121
Summary. 122

Antigen recognition by T cells. 123

3-10 The T-cell receptor is very similar to a Fab fragment of immunoglobulin. 123
3-11 A T-cell receptor recognizes antigen in the form of a complex of a foreign peptide bound to an MHC molecule. 125
3-12 There are two classes of MHC molecules with distinct subunit composition but similar three-dimensional structures. 126
3-13 Peptides are stably bound to MHC molecules, and also serve to stabilize the MHC molecule on the cell surface. 128
3-14 MHC class I molecules bind short peptides of 8–10 amino acids by both ends. 129
3-15 The length of the peptides bound by MHC class II molecules is not constrained. 130
3-16 The crystal structures of several MHC:peptide:T-cell receptor complexes show a similar T-cell receptor orientation over the MHC:peptide complex. 132
3-17 The CD4 and CD8 cell-surface proteins of T cells are required to make an effective response to antigen. 133
3-18 The two classes of MHC molecules are expressed differentially on cells. 135
3-19 A distinct subset of T cells bears an alternative receptor made up of γ and δ chains. 137
Summary. 137
Summary to Chapter 3. 138

Chapter 4 The Generation of Lymphocyte Antigen Receptors 143

Primary immunoglobulin gene rearrangement 144

4-1 Immunoglobulin genes are rearranged in antibody-producing cells. 144
4-2 Complete genes that encode a variable region are generated by the somatic recombination of separate gene segments. 145
4-3 Multiple contiguous V gene segments are present at each immunoglobulin locus. 146
4-4 Rearrangement of V, D, and J gene segments is guided by flanking DNA sequences. 148
4-5 The reaction that recombines V, D, and J gene segments involves both lymphocyte-specific and ubiquitous DNA-modifying enzymes. 150
4-6 The diversity of the immunoglobulin repertoire is generated by four main processes. 153
4-7 The multiple inherited gene segments are used in different combinations. 153

4-8 Variable addition and subtraction of nucleotides at the junctions between gene segments contributes to the diversity of the third hypervariable region. 154
Summary. 155

T-cell receptor gene rearrangement. 155

4-9 The T-cell receptor gene segments are arranged in a similar pattern to immunoglobulin gene segments and are rearranged by the same enzymes. 156
4-10 T-cell receptors concentrate diversity in the third hypervariable region. 157
4-11 γ:δ T-cell receptors are also generated by gene rearrangement. 158
Summary. 159

Structural variation in immunoglobulin constant regions. 160

4-12 Different classes of immunoglobulins are distinguished by the structure of their heavy-chain constant regions. 160
4-13 The constant region confers functional specialization on the antibody. 161
4-14 Mature naive B cells express both IgM and IgD at their surface. 163
4-15 Transmembrane and secreted forms of immunoglobulin are generated from alternative heavy-chain transcripts. 163
4-16 IgM and IgA can form polymers. 164
Summary. 166

Secondary diversification of the antibody repertoire. 167

4-17 Activation-induced cytidine deaminase introduces mutations in genes transcribed in B cells. 168
4-18 Rearranged V-region genes are further diversified by somatic hypermutation. 169
4-19 In some species, most immunoglobulin gene diversification occurs after gene rearrangement. 171
4-20 Class switching enables the same assembled V_H exon to be associated with different C_H genes in the course of an immune response. 171
Summary. 175
Summary to Chapter 4. 175

Chapter 5 Antigen Presentation to T Lymphocytes 181

The generation of T-cell receptor ligands. 182

5-1 The MHC class I and class II molecules deliver peptides to the cell surface from two intracellular compartments. 182
5-2 Peptides that bind to MHC class I molecules are actively transported from the cytosol to the endoplasmic reticulum. 183
5-3 Peptides for transport into the endoplasmic reticulum are generated in the cytosol. 184
5-4 Retrograde transport from the endoplasmic reticulum to the cytosol enables exogenous proteins to be processed for cross-presentation by MHC class I molecules. 186
5-5 Newly synthesized MHC class I molecules are retained in the endoplasmic reticulum until they bind a peptide. 187
5-6 Many viruses produce immunoevasins that interfere with antigen presentation by MHC class I molecules. 189
5-7 Peptides presented by MHC class II molecules are generated in acidified endocytic vesicles. 190
5-8 The invariant chain directs newly synthesized MHC class II molecules to acidified intracellular vesicles. 192
5-9 A specialized MHC class II-like molecule catalyzes loading of MHC class II molecules with peptides. 193
5-10 Stable binding of peptides by MHC molecules provides effective antigen presentation at the cell surface. 194
Summary. 195

The major histocompatibility complex and its functions. 196

5-11 Many proteins involved in antigen processing and presentation are encoded by genes within the major histocompatibility complex. 197
5-12 The protein products of MHC class I and class II genes are highly polymorphic. 199
5-13 MHC polymorphism affects antigen recognition by T cells by influencing both peptide binding and the contacts between T-cell receptor and MHC molecule. 201
5-14 Alloreactive T cells recognizing nonself MHC molecules are very abundant. 204
5-15 Many T cells respond to superantigens. 206
5-16 MHC polymorphism extends the range of antigens to which the immune system can respond. 207
5-17 A variety of genes with specialized functions in immunity are also encoded in the MHC. 208
5-18 Specialized MHC class I molecules act as ligands for the activation and inhibition of NK cells. 209
5-19 The CD1 family of MHC class I-like molecules is encoded outside the MHC and presents microbial lipids to CD1-restricted T cells. 211
Summary. 212
Summary to Chapter 5. 212

Part III THE DEVELOPMENT OF MATURE LYMPHOCYTE RECEPTOR REPERTOIRES

Chapter 6 Signaling Through Immune System Receptors 219

General principles of signal transduction. 220

6-1 Transmembrane receptors convert extracellular signals into intracellular biochemical events. 220
6-2 Intracellular signal transduction often takes place in large multiprotein signaling complexes. 221
6-3 The activation of some receptors generates small-molecule second messengers. 222
6-4 Small G proteins act as molecular switches in many different signaling pathways. 224
6-5 Signaling proteins are recruited to the membrane by a variety of mechanisms. 224
6-6 Signal transduction proteins are organized in the plasma membrane in structures called lipid rafts. 225
6-7 Protein degradation has an important role in terminating signaling responses. 226
Summary. 227

Antigen receptor signaling and lymphocyte activation. 227

6-8 The variable chains of antigen receptors are associated with invariant accessory chains that carry out the signaling function of the receptor. 228
6-9 Lymphocytes are extremely sensitive to their specific antigens. 229

6-10 Antigen binding leads to phosphorylation of the ITAM sequences associated with the antigen receptors. 231

6-11 In T cells, fully phosphorylated ITAMs bind the kinase ZAP-70 and enable it to be activated. 233

6-12 Activated Syk and ZAP-70 phosphorylate scaffold proteins that mediate many of the downstream effects of antigen receptor signaling. 233

6-13 PLC-γ is activated by Tec tyrosine kinases. 234

6-14 Activation of the small G protein Ras activates a MAP kinase cascade, resulting in the production of the transcription factor AP-1. 235

6-15 The transcription factor NFAT is indirectly activated by Ca^{2+}. 236

6-16 The transcription factor NFκB is activated by the actions of protein kinase C. 237

6-17 The logic of B-cell receptor signaling is similar to that of T-cell receptor signaling but some of the signaling components are specific to B cells. 239

6-18 ITAMs are also found in other receptors on leukocytes that signal for cell activation. 240

6-19 The cell-surface protein CD28 is a co-stimulatory receptor for naive T cells. 240

6-20 Inhibitory receptors on lymphocytes help regulate immune responses. 242

Summary. 244

Other receptors and signaling pathways. 244

6-21 Cytokines typically activate fast signaling pathways that end in the nucleus. 245

6-22 Cytokine receptors form dimers or trimers on ligand binding. 245

6-23 Cytokine receptors are associated with the JAK family of tyrosine kinases which activate STAT transcription factors. 245

6-24 Cytokine signaling is terminated by a negative feedback mechanism. 246

6-25 The receptors that induce apoptosis activate specialized intracellular proteases called caspases. 247

6-26 The intrinsic pathway of apoptosis is mediated by release of cytochrome *c* from mitochondria. 249

6-27 Microbes and their products act via Toll-like receptors to activate NFκB. 249

6-28 Bacterial peptides, mediators of inflammatory responses, and chemokines signal through members of the G-protein-coupled receptor family. 251

Summary. 253

Summary to Chapter 6. 253

Chapter 7 The Development and Survival of Lymphocytes 257

Development of B lymphocytes 259

7-1 Lymphocytes derive from hematopoietic stem cells in the bone marrow. 259

7-2 B-cell development begins by rearrangement of the heavy-chain locus. 262

7-3 The pre-B-cell receptor tests for successful production of a complete heavy chain and signals for proliferation of pro-B cells. 264

7-4 Pre-B-cell receptor signaling inhibits further heavy-chain locus rearrangement and enforces allelic exclusion. 266

7-5 Pre-B cells rearrange the light-chain locus and express cell-surface immunoglobulin. 266

7-6 Immature B cells are tested for autoreactivity before they leave the bone marrow. 268

Summary. 272

T-cell development in the thymus. 273

7-7 T-cell progenitors originate in the bone marrow, but all the important events in their development occur in the thymus. 274

7-8 T-cell precursors proliferate extensively in the thymus but most die there. 275

7-9 Successive stages in the development of thymocytes are marked by changes in cell-surface molecules. 277

7-10 Thymocytes at different developmental stages are found in distinct parts of the thymus. 279

7-11 T cells with α:β or γ:δ receptors arise from a common progenitor. 280

7-12 T cells expressing particular γ- and δ-chain V regions arise in an ordered sequence early in life. 282

7-13 Successful synthesis of a rearranged β chain allows the production of a pre-T-cell receptor that triggers cell proliferation and blocks further β-chain gene rearrangement. 283

7-14 T-cell α-chain genes undergo successive rearrangements until positive selection or cell death intervenes. 286

Summary. 288

Positive and negative selection of T cells. 288

7-15 The MHC type of the thymic stroma selects a repertoire of mature T cells that can recognize foreign antigens presented by the same MHC type. 289

7-16 Only thymocytes whose receptors interact with self-peptide:self-MHC complexes can survive and mature. 290

7-17 Positive selection acts on a repertoire of T-cell receptors with inherent specificity for MHC molecules. 291

7-18 Positive selection coordinates the expression of CD4 or CD8 with the specificity of the T-cell receptor and the potential effector functions of the T cell. 292

7-19 Thymic cortical epithelial cells mediate positive selection of developing thymocytes. 293

7-20 T cells that react strongly with ubiquitous self antigens are deleted in the thymus. 294

7-21 Negative selection is driven most efficiently by bone marrow derived antigen-presenting cells. 296

7-22 The specificity and/or the strength of signals for negative and positive selection must differ. 297

Summary. 298

Survival and maturation of lymphocytes in peripheral lymphoid tissues. 299

7-23 Different lymphocyte subsets are found in particular locations in peripheral lymphoid tissues. 299

7-24 The development and organization of peripheral lymphoid tissues are controlled by proteins of the tumor necrosis factor family. 300

7-25 The homing of lymphocytes to specific regions of peripheral lymphoid tissues is mediated by chemokines. 302

7-26 Lymphocytes that encounter sufficient quantities of self antigens for the first time in the periphery are eliminated or inactivated. 303

7-27 Most immature B cells arriving in the spleen are short-lived and require cytokines and positive signals through the B-cell receptor for maturation and survival. 304

7-28 B-1 cells and marginal zone B cells are distinct B-cell subtypes with unique antigen receptor specificity. 306

7-29 T-cell homeostasis in the periphery is regulated by cytokines and self-MHC interactions. 307

Summary. 307

Lymphoid tumors. **308**
7-30 B-cell tumors often occupy the same site as their normal counterparts. 308
7-31 T-cell tumors correspond to a small number of stages of T-cell development. 311
7-32 B-cell lymphomas frequently carry chromosomal translocations that join immunoglobulin loci to genes that regulate cell growth. 312
Summary. 312
Summary to Chapter 7. 313

Part IV THE ADAPTIVE IMMUNE RESPONSE

Chapter 8 T Cell-Mediated Immunity **323**

Entry of naive T cells and antigen-presenting cells into peripheral lymphoid organs. **325**
8-1 Naive T cells migrate through peripheral lymphoid tissues, sampling the peptide:MHC complexes on dendritic cell surfaces. 325
8-2 Lymphocyte entry into lymphoid tissues depends on chemokines and adhesion molecules. 326
8-3 Activation of integrins by chemokines is responsible for the entry of naive T cells into lymph nodes. 327
8-4 T-cell responses are initiated in peripheral lymphoid organs by activated dendritic cells. 331
8-5 There are two different functional classes of dendritic cells. 332
8-6 Dendritic cells process antigens from a wide array of pathogens. 334
8-7 Pathogen-induced TLR signaling in immature dendritic cells induces their migration to lymphoid organs and enhances antigen processing. 336
8-8 Plasmacytoid dendritic cells detect viral infections and generate abundant type I interferons and pro-inflammatory cytokines. 338
8-9 Macrophages are scavenger cells that can be induced by pathogens to present foreign antigens to naive T cells. 339
8-10 B cells are highly efficient at presenting antigens that bind to their surface immunoglobulin. 340
Summary. 342

Priming of naive T cells by pathogen-activated dendritic cells. **343**
8-11 Cell-adhesion molecules mediate the initial interaction of naive T cells with antigen-presenting cells. 343
8-12 Antigen-presenting cells deliver three kinds of signals for clonal expansion and differentiation of naive T cells. 344
8-13 CD28-dependent co-stimulation of activated T cells induces expression of the T-cell growth factor interleukin-2 and the high-affinity IL-2 receptor. 345
8-14 Signal 2 can be modified by additional co-stimulatory pathways. 346
8-15 Antigen recognition in the absence of co-stimulation l eads to functional inactivation or clonal deletion of peripheral T cells. 347
8-16 Proliferating T cells differentiate into effector T cells that do not require co-stimulation to act. 349
8-17 T cells differentiate into several subsets of functionally different effector cells. 349
8-18 CD8 T cells can be activated in different ways to become cytotoxic effector cells. 352
8-19 Various forms of signal 3 induce the differentiation of naive CD4 T cells down distinct effector pathways. 352
8-20 Regulatory CD4 T cells are involved in controlling adaptive immune responses. 354
Summary. 356

General properties of effector T cells and their cytokines. **356**
8-21 Effector T-cell interactions with target cells are initiated by antigen-nonspecific cell-adhesion molecules. 357
8-22 Binding of the T-cell receptor complex directs the release of effector molecules and focuses them on the target cell. 357
8-23 The effector functions of T cells are determined by the array of effector molecules that they produce. 358
8-24 Cytokines can act locally or at a distance. 359
8-25 Cytokines and their receptors fall into distinct families of structurally related proteins. 361
8-26 The TNF family of cytokines are trimeric proteins that are usually associated with the cell surface. 362
Summary. 363

T cell-mediated cytotoxicity. **364**
8-27 Cytotoxic T cells can induce target cells to undergo programmed cell death. 364
8-28 Cytotoxic effector proteins that trigger apoptosis are contained in the granules of CD8 cytotoxic T cells. 365
8-29 Cytotoxic T cells are selective and serial killers of targets expressing a specific antigen. 367
8-30 Cytotoxic T cells also act by releasing cytokines. 368
Summary. 368

Macrophage activation by T_H1 cells. **368**
8-31 T_H1 cells have a central role in macrophage activation. 369
8-32 Activation of macrophages by T_H1 cells promotes microbial killing and must be tightly regulated to avoid tissue damage. 370
8-33 T_H1 cells coordinate the host response to intracellular pathogens. 371
Summary. 372
Summary to Chapter 8. 372

Chapter 9 The Humoral Immune Response **379**

B-cell activation and antibody production. **381**
9-1 The humoral immune response is initiated when B cells that bind antigen are signaled by helper T cells or by certain microbial antigens alone. 381
9-2 B-cell responses to antigen are enhanced by co-ligation of the B-cell co-receptor. 382
9-3 Helper T cells activate B cells that recognize the same antigen. 383
9-4 Antigenic peptides bound to self-MHC class II molecules on B cells trigger helper T cells to make membrane-bound and secreted molecules that can activate a B cell. 384
9-5 B cells that have bound antigen via their B-cell receptor are trapped in the T-cell zones of secondary lymphoid tissues. 386

9-6 Antibody-secreting plasma cells differentiate from activated B cells. 387

9-7 The second phase of a primary B-cell immune response occurs when activated B cells migrate to follicles and proliferate to form germinal centers. 388

9-8 Germinal center B cells undergo V-region somatic hypermutation, and cells with mutations that improve affinity for antigen are selected. 390

9-9 Class switching in thymus-dependent antibody responses requires expression of CD40 ligand by the helper T cell and is directed by cytokines. 392

9-10 Ligation of the B-cell receptor and CD40, together with direct contact with T cells, are all required to sustain germinal center B cells. 394

9-11 Surviving germinal center B cells differentiate into either plasma cells or memory cells. 395

9-12 B-cell responses to bacterial antigens with intrinsic ability to activate B cells do not require T-cell help. 396

9-13 B-cell responses to bacterial polysaccharides do not require peptide-specific T-cell help. 397

Summary. 399

The distribution and functions of immunoglobulin isotypes. 400

9-14 Antibodies of different isotypes operate in distinct places and have distinct effector functions. 400

9-15 Transport proteins that bind to the Fc regions of antibodies carry particular isotypes across epithelial barriers. 402

9-16 High-affinity IgG and IgA antibodies can neutralize bacterial toxins. 404

9-17 High-affinity IgG and IgA antibodies can inhibit the infectivity of viruses. 405

9-18 Antibodies can block the adherence of bacteria to host cells. 406

9-19 Antibody:antigen complexes activate the classical pathway of complement by binding to C1q. 406

9-20 Complement receptors are important in the removal of immune complexes from the circulation. 408

Summary. 409

The destruction of antibody-coated pathogens via Fc receptors. 409

9-21 The Fc receptors of accessory cells are signaling receptors specific for immunoglobulins of different classes. 410

9-22 Fc receptors on phagocytes are activated by antibodies bound to the surface of pathogens and enable the phagocytes to ingest and destroy pathogens. 411

9-23 Fc receptors activate NK cells to destroy antibody-coated targets. 412

9-24 Mast cells, basophils, and activated eosinophils bind IgE antibody via the high-affinity Fcε receptor. 413

9-25 IgE-mediated activation of accessory cells has an important role in resistance to parasite infection. 414

Summary. 415

Summary to Chapter 9. 416

Chapter 10 Dynamics of Adaptive Immunity 421

The course of the immune response to infection. 422

10-1 The course of an infection can be divided into several distinct phases. 422

10-2 The nonspecific responses of innate immunity are necessary for an adaptive immune response to be initiated. 425

10-3 Cytokines made in the earliest phase of an infection influence differentiation of CD4 T cells toward the T_H17 subset. 426

10-4 Cytokines made in the later stages of an infection influence differentiation of CD4 T cells toward T_H1 or T_H2 cells. 427

10-5 The distinct subsets of CD4 T cells can regulate each other's differentiation. 430

10-6 Effector T cells are guided to sites of infection by chemokines and newly expressed adhesion molecules. 432

10-7 Differentiated effector T cells are not a static population but continue to respond to signals as they carry out their effector functions. 434

10-8 Primary CD8 T-cell responses to pathogens can occur in the absence of CD4 help. 435

10-9 Antibody responses develop in lymphoid tissues under the direction of CD4 helper T cells. 437

10-10 Antibody responses are sustained in medullary cords and bone marrow. 438

10-11 The effector mechanisms used to clear an infection depend on the infectious agent. 439

10-12 Resolution of an infection is accompanied by the death of most of the effector cells and the generation of memory cells. 441

Summary. 441

Immunological memory 442

10-13 Immunological memory is long-lived after infection or vaccination. 442

10-14 Memory B-cell responses differ in several ways from those of naive B cells. 444

10-15 Repeated immunization leads to increasing affinity of antibody due to somatic hypermutation and selection by antigen in germinal centers. 445

10-16 Memory T cells are increased in frequency compared with naive T cells specific for the same antigen and have distinct activation requirements and cell-surface proteins that distinguish them from effector T cells. 446

10-17 Memory T cells are heterogeneous and include central memory and effector memory subsets. 449

10-18 CD4 T-cell help is required for CD8 T-cell memory and involves CD40 and IL-2 signaling. 450

10-19 In immune individuals, secondary and subsequent responses are mainly attributable to memory lymphocytes. 452

Summary. 453

Summary to Chapter 10. 454

Chapter 11 The Mucosal Immune System 459

The organization of the mucosal immune system. 459

11-1 The mucosal immune system protects the internal surfaces of the body. 4459

11-2 The mucosal immune system may be the original vertebrate immune system. 461

11-3 Mucosa-associated lymphoid tissue is located in anatomically defined compartments in the gut. 462

11-4 The intestine has distinctive routes and mechanisms of antigen uptake. 464

11-5 The mucosal immune system contains large numbers of effector lymphocytes even in the absence of disease. 466
11-6 The circulation of lymphocytes within the mucosal immune system is controlled by tissue-specific adhesion molecules and chemokine receptors. 467
11-7 Priming of lymphocytes in one mucosal tissue can induce protective immunity at other mucosal surfaces. 469
11-8 Secretory IgA is the class of antibody associated with the mucosal immune system. 469
11-9 IgA deficiency is common in humans but may be overcome by secretory IgM. 472
11-10 The mucosal immune system contains unusual T lymphocytes. 472
Summary. 475

The mucosal response to infection and regulation of mucosal immune responses. 476

11-11 Enteric pathogens cause a local inflammatory response and the development of protective immunity. 476
11-12 The outcome of infection by intestinal pathogens is determined by a complex interplay between the microorganism and the host immune response. 478
11-13 The mucosal immune system must maintain a balance between protective immunity and homeostasis to a large number of different foreign antigens. 480
11-14 The healthy intestine contains large quantities of bacteria but does not generate productive immunity against them. 482
11-15 Full immune responses to commensal bacteria provoke intestinal disease. 485
11-16 Intestinal helminths provoke strong T_H2-mediated immune responses. 485
11-17 Other eukaryotic parasites provoke protective immunity and pathology in the gut. 488
11-18 Dendritic cells at mucosal surfaces favor the induction of tolerance under physiological conditions and maintain the presence of physiological inflammation. 488
Summary. 489
Summary to Chapter 11. 490

Part V THE IMMUNE SYSTEM IN HEALTH AND DISEASE

Chapter 12 Failures of Host Defense Mechanisms 497

Evasion and subversion of immune defenses 498

12-1 Antigenic variation allows pathogens to escape from immunity. 498
12-2 Some viruses persist *in vivo* by ceasing to replicate until immunity wanes. 501
12-3 Some pathogens resist destruction by host defense mechanisms or exploit them for their own purposes. 502
12-4 Immunosuppression or inappropriate immune responses can contribute to persistent disease. 504
12-5 Immune responses can contribute directly to pathogenesis. 506
12-6 Regulatory T cells can affect the outcome of infectious disease. 506
Summary. 507

Immunodeficiency diseases. 507

12-7 A history of repeated infections suggests a diagnosis of immunodeficiency. 507
12-8 Inherited immunodeficiency diseases are caused by recessive gene defects. 508
12-9 The main effect of low levels of antibody is an inability to clear extracellular bacteria. 509
12-10 Some antibody deficiencies can be due to defects in either B-cell or T-cell function. 512
12-11 Defects in complement components cause defective humoral immune function. 514
12-12 Defects in phagocytic cells permit widespread bacterial infections. 515
12-13 Defects in T-cell differentiation can result in severe combined immunodeficiencies. 517
12-14 Defects in antigen receptor gene rearrangement result in SCID. 519
12-15 Defects in signaling from T-cell antigen receptors can cause severe immunodeficiency. 520
12-16 Genetic defects in thymic function that block T-cell development result in severe immunodeficiencies. 520
12-17 The normal pathways for host defense against intracellular bacteria are pinpointed by genetic deficiencies of IFN-γ and IL-12 and their receptors. 522
12-18 X-linked lymphoproliferative syndrome is associated with fatal infection by Epstein–Barr virus and with the development of lymphomas. 523
12-19 Genetic abnormalities in the secretory cytotoxic pathway of lymphocytes cause uncontrolled lymphoproliferation and inflammatory responses to viral infections. 523
12-20 Bone marrow transplantation or gene therapy can be useful to correct genetic defects. 525
12-21 Secondary immunodeficiencies are major predisposing causes of infection and death. 526
Summary. 527

Acquired immune deficiency syndrome. 527

12-22 Most individuals infected with HIV progress over time to AIDS. 528
12-23 HIV is a retrovirus that infects CD4 T cells, dendritic cells, and macrophages. 530
12-24 Genetic variation in the host can alter the rate of progression of disease. 532
12-25 A genetic deficiency of the co-receptor CCR5 confers resistance to HIV infection *in vivo*. 532
12-26 HIV RNA is transcribed by viral reverse transcriptase into DNA that integrates into the host-cell genome. 534
12-27 Replication of HIV occurs only in activated T cells. 536
12-28 Lymphoid tissue is the major reservoir of HIV infection. 537
12-29 An immune response controls but does not eliminate HIV. 538
12-30 The destruction of immune function as a result of HIV infection leads to increased susceptibility to opportunistic infection and eventually to death. 540
12-31 Drugs that block HIV replication lead to a rapid decrease in titer of infectious virus and an increase in CD4 T cells. 540
12-32 HIV accumulates many mutations in the course of infection, and drug treatment is soon followed by the outgrowth of drug-resistant variants. 542
12-33 Vaccination against HIV is an attractive solution but poses many difficulties. 543

12-34 Prevention and education are one way in which the spread of HIV and AIDS can be controlled. 545

Summary. 545

Summary to Chapter 12. 546

Chapter 13 Allergy and Hypersensitivity 555

Sensitization and the production of IgE. 557

13-1 Allergens are often delivered transmucosally at low dose, a route that favors IgE production. 557

13-2 Enzymes are frequent triggers of allergy. 558

13-3 Class switching to IgE in B lymphocytes is favored by specific signals. 559

13-4 Both genetic and environmental factors contribute to the development of IgE-mediated allergy. 560

13-5 Regulatory T cells can control allergic responses. 565

Summary. 565

Effector mechanisms in allergic reactions. 566

13-6 Most IgE is cell-bound and engages effector mechanisms of the immune system by different pathways from other antibody isotypes. 567

13-7 Mast cells reside in tissues and orchestrate allergic reactions. 567

13-8 Eosinophils are normally under tight control to prevent inappropriate toxic responses. 569

13-9 Eosinophils and basophils cause inflammation and tissue damage in allergic reactions. 571

13-10 Allergic reactions can be divided into immediate and late-phase responses. 571

13-11 The clinical effects of allergic reactions vary according to the site of mast-cell activation. 572

13-12 Allergen inhalation is associated with the development of rhinitis and asthma. 574

13-13 Skin allergy is manifested as urticaria or chronic eczema. 576

13-14 Allergy to foods causes systemic reactions as well as symptoms limited to the gut. 577

13-15 Celiac disease is a model of antigen-specific immunopathology. 578

13-16 Allergy can be treated by inhibiting either IgE production or the effector pathways activated by the cross-linking of cell-surface IgE. 580

Summary. 583

Hypersensitivity diseases. 583

13-17 Innocuous antigens can cause type II hypersensitivity reactions in susceptible individuals by binding to the surfaces of circulating blood cells. 583

13-18 Systemic disease caused by immune-complex formation can follow the administration of large quantities of poorly catabolized antigens. 583

13-19 Delayed-type hypersensitivity reactions are mediated by T_H1 cells and CD8 cytotoxic T cells. 585

13-20 Mutation in the molecular regulators of inflammation can cause hypersensitive inflammatory responses resulting in 'autoinflammatory disease.' 588

13-21 Crohn's disease is a relatively common inflammatory disease with a complex etiology. 590

Summary. 591

Summary to Chapter 13. 591

Chapter 14 Autoimmunity and Transplantation 599

The making and breaking of self-tolerance 600

14-1 A critical function of the immune system is to discriminate self from nonself. 600

14-2 Multiple tolerance mechanisms normally prevent autoimmunity. 602

14-3 Central deletion or inactivation of newly formed lymphocytes is the first checkpoint of self-tolerance. 603

14-4 Lymphocytes that bind self antigens with relatively low affinity usually ignore them but in some circumstances become activated. 603

14-5 Antigens in immunologically privileged sites do not induce immune attack but can serve as targets. 605

14-6 Autoreactive T cells that express particular cytokines may be nonpathogenic or may suppress pathogenic lymphocytes. 606

14-7 Autoimmune responses can be controlled at various stages by regulatory T cells. 607

Summary. 609

Autoimmune diseases and pathogenic mechanisms. 610

14-8 Specific adaptive immune responses to self antigens can cause autoimmune disease. 610

14-9 Autoimmune diseases can be classified into clusters that are typically either organ-specific or systemic. 611

14-10 Multiple aspects of the immune system are typically recruited in autoimmune disease. 612

14-11 Chronic autoimmune disease develops through positive feedback from inflammation, inability to clear the self antigen, and a broadening of the autoimmune response. 615

14-12 Both antibody and effector T cells can cause tissue damage in autoimmune disease. 617

14-13 Autoantibodies against blood cells promote their destruction. 617

14-14 The fixation of sublytic doses of complement to cells in tissues stimulates a powerful inflammatory response. 619

14-15 Autoantibodies against receptors cause disease by stimulating or blocking receptor function. 620

14-16 Autoantibodies against extracellular antigens cause inflammatory injury by mechanisms akin to type II and type III hypersensitivity reactions. 621

14-17 T cells specific for self antigens can cause direct tissue injury and sustain autoantibody responses. 622

Summary. 625

The genetic and environmental basis of autoimmunity. 626

14-18 Autoimmune diseases have a strong genetic component. 626

14-19 A defect in a single gene can cause autoimmune disease. 627

14-20 Several approaches have given us insight into the genetic basis of autoimmunity. 628

14-21 Genes that predispose to autoimmunity fall into categories that affect one or more of the mechanisms of tolerance. 631

14-22 MHC genes have an important role in controlling susceptibility to autoimmune disease. 631

14-23 External events can initiate autoimmunity. 634

14-24 Infection can lead to autoimmune disease by providing an environment that promotes lymphocyte activation. 634

14-25 Cross-reactivity between foreign molecules on pathogens and self molecules can lead to anti-self responses and autoimmune disease. 635

14-26 Drugs and toxins can cause autoimmune syndromes. 636
14-27 Random events may be required for the initiation of autoimmunity. 637
Summary. 637

Responses to alloantigens and transplant rejection. 637
14-28 Graft rejection is an immunological response mediated primarily by T cells. 638
14-29 Matching donor and recipient at the MHC improves the outcome of transplantation. 639
14-30 In MHC-identical grafts, rejection is caused by peptides from other alloantigens bound to graft MHC molecules. 640
14-31 There are two ways of presenting alloantigens on the transplant to the recipient's T lymphocytes. 641
14-32 Antibodies reacting with endothelium cause hyperacute graft rejection. 642
14-33 Chronic organ rejection is caused by inflammatory vascular injury to the graft. 643
14-34 A variety of organs are transplanted routinely in clinical medicine. 644
14-35 The converse of graft rejection is graft-versus-host disease. 645
14-36 Regulatory T cells are involved in alloreactive immune responses. 646
14-37 The fetus is an allograft that is tolerated repeatedly. 647
Summary. 648
Summary to Chapter 14. 648

Chapter 15 Manipulation of the Immune Response 655

Extrinsic regulation of unwanted immune responses. 655
15-1 Corticosteroids are powerful anti-inflammatory drugs that alter the transcription of many genes. 656
15-2 Cytotoxic drugs cause immunosuppression by killing dividing cells and have serious side-effects. 657
15-3 Cyclosporin A, tacrolimus (FK506), and rapamycin (sirolimus) are powerful immunosuppressive agents that interfere with T-cell signaling. 658
15-4 Immunosuppressive drugs are valuable probes of intracellular signaling pathways in lymphocytes. 659
15-5 Antibodies against cell-surface molecules have been used to remove specific lymphocyte subsets or to inhibit cell function. 661
15-6 Antibodies can be engineered to reduce their immunogenicity in humans. 661
15-7 Monoclonal antibodies can be used to prevent allograft rejection. 662
15-8 Biological agents can be used to alleviate and suppress autoimmune disease. 664
15-9 Depletion or inhibition of autoreactive lymphocytes can treat autoimmune disease. 666
15-10 Interference with co-stimulatory pathways for the activation of lymphocytes could be a treatment for autoimmune disease. 668
15-11 Induction of regulatory T cells by antibody therapy can inhibit autoimmune disease. 668
15-12 A number of commonly used drugs have immunomodulatory properties. 669
15-13 Controlled administration of antigen can be used to manipulate the nature of an antigen-specific response. 671
Summary. 672

Using the immune response to attack tumors. 672
15-14 The development of transplantable tumors in mice led to the discovery of protective immune responses to tumors. 673
15-15 Tumors can escape rejection in many ways. 674
15-16 T lymphocytes can recognize specific antigens on human tumors, and adoptive T-cell transfer is being tested in cancer patients. 678
15-17 Monoclonal antibodies against tumor antigens, alone or linked to toxins, can control tumor growth. 682
15-18 Enhancing the immune response to tumors by vaccination holds promise for cancer prevention and therapy. 684
Summary. 687

Manipulating the immune response to fight infection. 687
15-19 There are several requirements for an effective vaccine. 689
15-20 The history of vaccination against *Bordetella pertussis* illustrates the importance of developing an effective vaccine that is perceived to be safe. 690
15-21 Conjugate vaccines have been developed as a result of understanding how T and B cells collaborate in an immune response. 691
15-22 The use of adjuvants is another important approach to enhancing the immunogenicity of vaccines. 693
15-23 Live-attenuated viral vaccines are usually more potent than 'killed' vaccines and can be made safer by the use of recombinant DNA technology. 695
15-24 Live-attenuated bacterial vaccines can be developed by selecting nonpathogenic or disabled mutants. 696
15-25 Synthetic peptides of protective antigens can elicit protective immunity. 696
15-26 The route of vaccination is an important determinant of success. 697
15-27 Protective immunity can be induced by injecting DNA encoding microbial antigens and human cytokines into muscle. 698
15-28 The effectiveness of a vaccine can be enhanced by targeting it to sites of antigen presentation. 699
15-29 An important question is whether vaccination can be used therapeutically to control existing chronic infections. 700
15-30 Modulation of the immune system might be used to inhibit immunopathological responses to infectious agents. 701
Summary. 702
Summary to Chapter 15. 703

Part VI THE ORIGINS OF IMMUNE RESPONSES

Chapter 16 Evolution of the Immune System 711

Evolution of the innate immune system. 712
16-1 The evolution of the immune system can be studied by comparing the genes expressed by different species. 712
16-2 Antimicrobial peptides are likely to be the most ancient immune defenses. 713
16-3 Toll-like receptors may represent the most ancient pathogen-recognition system. 714
16-4 Toll-like receptor genes have undergone extensive diversification in some invertebrate species. 716

16-5 A second recognition system in *Drosophila* homologous to the mammalian TNF receptor pathway provides protection from Gram-negative bacteria. 717
16-6 An ancestral complement system opsonizes pathogens for uptake by phagocytic cells. 717
16-7 The lectin pathway of complement activation evolved in invertebrates. 719
Summary. 720

Evolution of the adaptive immune response. 720
16-8 Some invertebrates generate extensive diversity in a repertoire of immunoglobulin-like genes. 721
16-9 Agnathans possess an adaptive immune system that uses somatic gene rearrangement to diversify receptors built from LRR domains. 722
16-10 Adaptive immunity based on a diversified repertoire of immunoglobulin-like genes appeared abruptly in the cartilaginous fish. 724
16-11 The target of the transposon is likely to have been a gene encoding a cell-surface receptor containing an immunoglobulin-like V domain. 725
16-12 Different species generate immunoglobulin diversity in different ways. 726
16-13 Both $\alpha{:}\beta$ and $\gamma{:}\delta$ T-cell receptors are present in cartilaginous fish. 727
16-14 MHC class I and class II molecules are also first found in the cartilaginous fishes. 728
Summary. 729
Summary to Chapter 16. 729

Appendix I Immunologists' Toolbox 735

Immunization. 735
A-1 Haptens. 736
A-2 Routes of immunization. 738
A-3 Effects of antigen dose. 738
A-4 Adjuvants. 738

The detection, measurement, and characterization of antibodies and their use as research and diagnostic tools. 740
A-5 Affinity chromatography. 741
A-6 Radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), and competitive inhibition assay. 741
A-7 Hemagglutination and blood typing. 743
A-8 Precipitin reaction. 744
A-9 Equilibrium dialysis: measurement of antibody affinity and avidity. 745
A-10 Anti-immunoglobulin antibodies. 746
A-11 Coombs tests and the detection of Rhesus incompatibility. 747
A-12 Monoclonal antibodies. 749
A-13 Phage display libraries for antibody V-region production. 750
A-14 Immunofluorescence microscopy. 751
A-15 Immunoelectron microscopy. 753
A-16 Immunohistochemistry. 753
A-17 Immunoprecipitation and co-immunoprecipitation. 754
A-18 Immunoblotting (Western blotting). 755
A-19 Use of antibodies in the isolation and identification of genes and their products. 756

Isolation of lymphocytes. 758
A-20 Isolation of peripheral blood lymphocytes by Ficoll-Hypaque™ gradient. 758
A-21 Isolation of lymphocytes from tissues other than blood. 758
A-22 Flow cytometry and FACS analysis. 759
A-23 Lymphocyte isolation using antibody-coated magnetic beads. 761
A-24 Isolation of homogeneous T-cell lines. 761

Characterization of lymphocyte specificity, frequency, and function. 762
A-25 Limiting-dilution culture. 763
A-26 ELISPOT assays. 763
A-27 Identification of functional subsets of T cells by staining for cytokines. 764
A-28 Identification of T-cell receptor specificity using MHC:peptide tetramers. 765
A-29 Assessing the diversity of the T-cell repertoire by 'spectratyping.' 766
A-30 Biosensor assays for measuring the rates of association and disassociation of antigen receptors for their ligands. 767
A-31 Stimulation of lymphocyte proliferation by treatment with polyclonal mitogens or specific antigen. 769
A-32 Measurements of apoptosis by the TUNEL assay. 770
A-33 Assays for cytotoxic T cells. 770
A-34 Assays for CD4 T cells. 770
A-35 DNA microarrays. 772

Detection of immunity *in vivo*. 772
A-36 Assessment of protective immunity. 772
A-37 Transfer of protective immunity. 773
A-38 The tuberculin test. 774
A-39 Testing for allergic responses. 774
A-40 Assessment of immune responses and immunological competence in humans. 775
A-41 The Arthus reaction. 776

Manipulation of the immune system. 777
A-42 Adoptive transfer of lymphocytes. 777
A-43 Hematopoietic stem-cell transfers. 777
A-44 *In vivo* depletion of T cells. 777
A-45 *In vivo* depletion of B cells. 778
A-46 Transgenic mice. 778
A-47 Gene knockout by targeted disruption. 779

Appendix II CD Antigens 783

Appendix III Cytokines and their receptors 799

Appendix IV Chemokines and their receptors 802

Appendix V Immunological constants 804

Biographies 805

Glossary 806

Index 835